Long-term safety and effectiveness of the Fantom bioresorbable coronary artery scaffold: final results of the FANTOM II trial

Lutz, Matthias; Abizaid, Alexandre; Nielsen Holck, Emil; Lansky, Alexandra; Carrié, Didier; Weber-Albers, Joachim; Dudek, Darius; Frey, Norbert; Christiansen, Evald Høj; Holm, Niels Ramsing; Stone, Gregg W.
EuroIntervention ; 20(7): e453-e456, abr.2024.
Artículo en Inglés | SES-SP, SESSP-IDPCPROD, SES-SP | ID: biblio-1538279

Documentos relacionados

  1. Comparison of 1-Month and 12-Month Vessel Responses Between the Polymer-Free Biolimus A9-Coated Stent and the Durable Polymer Everolimus-Eluting Stent.
  2. Ultrathin-strut vs thin-strut drug-eluting stents for multi and single-stent lesions: A lesion-level subgroup analysis of 2 randomized trials.
  3. Impact of post-implantation time on bioresorbable vascular scaffold outcomes for type C versus non-type C coronary lesions: A longer-term study.
  4. Bioresorbable stents: We have more work to do.
  5. Ultrathin bioresorbable polymer sirolimus-eluting stents in US patients undergoing coronary revascularization: 1-Year outcomes from the BIOFLOW VII trial.
  6. Impact of diabetes on clinical outcomes after revascularization with the dual therapy CD34 antibody-covered sirolimus-eluting Combo stent and the sirolimus-eluting Orsiro stent.
  7. Elastic stent recoil in coronary total occlusions: Comparison of durable-polymer zotarolimus eluting stent and ultrathin strut bioabsorbable-polymer sirolimus eluting stent.
  8. Long-term serial functional evaluation after implantation of the Fantom sirolimus-eluting bioresorbable coronary scaffold.
  9. Biodegradable polymer drug-eluting stents: caveat emptor.
  10. Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial.